{
    "clinical_study": {
        "@rank": "63950", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: BMS-919373", 
                "arm_group_type": "Experimental", 
                "description": "BMS-919373 oral Solution single dose for one day"
            }, 
            {
                "arm_group_label": "Arm B: Sotalol", 
                "arm_group_type": "Active Comparator", 
                "description": "Sotalol oral Tablet single dose for one day"
            }, 
            {
                "arm_group_label": "Arm C: Placebo for BMS-919373", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral solution one single dose for one day"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the effect of  our compound (BMS-919373) on electrical activity of the heart\n      using pacemakers."
        }, 
        "brief_title": "Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Eligible patients will have a  dual-chamber permanent pacemaker without a history of\n             atrial fibrillation\n\n          -  Women who are not of childbearing potential\n\n        Exclusion Criteria:\n\n          -  History of Transient Ischemic Attack (TIA) or stroke in the last 12 months\n\n          -  History of clinically significant ventricular arrhythmia (not including isolated\n             monomorphic Premature Ventricular Contractions (PVCs)). Such arrhythmias are marked\n             by loss of consciousness, emergent cardioversion or defibrillation or unstable vital\n             signs requiring medical intervention\n\n          -  Complete heart block\n\n          -  Planned surgery, endovascular intervention or cardioversion within the study period\n\n          -  Use of Statin therapy\n\n          -  History of atrial fibrillation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153437", 
            "org_study_id": "CV205-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: BMS-919373", 
                "intervention_name": "BMS-919373", 
                "intervention_type": "Drug", 
                "other_name": "iKUR"
            }, 
            {
                "arm_group_label": "Arm B: Sotalol", 
                "intervention_name": "Sotalol", 
                "intervention_type": "Drug", 
                "other_name": "Co Sotalol"
            }, 
            {
                "arm_group_label": "Arm C: Placebo for BMS-919373", 
                "intervention_name": "Placebo for BMS-919373", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sotalol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker", 
            "safety_issue": "No", 
            "time_frame": "At 0.5, 1, 2, and 4 hours following study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153437"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "At 1, 2, and 4 hours following study drug administration"
            }, 
            {
                "measure": "Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At 2 hour following study drug administration"
            }, 
            {
                "measure": "Safety assessments based on Atrioventricular interval (AVI) and change from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At 1, 2, and 4 hours following study drug administration"
            }, 
            {
                "measure": "Safety assessments based on Wenckebach cycle length (WCL) and change from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At 1, 2, and 4 hours following study drug administration"
            }, 
            {
                "measure": "Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "At 1, 2, and 4 hours following study drug administration"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}